相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A small-cell lung cancer genome with complex signatures of tobacco exposure
Erin D. Pleasance et al.
NATURE (2010)
A comprehensive catalogue of somatic mutations from a human cancer genome
Erin D. Pleasance et al.
NATURE (2010)
Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses
Eduardo J. Villablanca et al.
NATURE MEDICINE (2010)
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesniere et al.
ONCOGENE (2010)
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses
Marij J. P. Welters et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Clinical Use of Anti-CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells
Andrew J. Rech et al.
CANCER VACCINES (2009)
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments
Ilona Kryczek et al.
BLOOD (2009)
Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy
Robbert G. van der Most et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Cancer Vaccine Enhanced, Non-Tumor-Reactive CD8+ T Cells Exhibit a Distinct Molecular Program Associated with Division Arrest Anergy
Marc Beyer et al.
CANCER RESEARCH (2009)
Chemotherapy induces ATP release from tumor cells
Isabelle Martins et al.
CELL CYCLE (2009)
HLA Class I-Associated Immunodominance Affects CTL Responsiveness to an ESO Recombinant Protein Tumor Antigen Vaccine
Gilles Bioley et al.
CLINICAL CANCER RESEARCH (2009)
Vaccination with Recombinant NY-ESO-1 Protein Elicits Immunodominant HLA-DR52b-restricted CD4+ T Cell Responses with a Conserved T Cell Receptor Repertoire
Gilles Bioley et al.
CLINICAL CANCER RESEARCH (2009)
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko et al.
CLINICAL CANCER RESEARCH (2009)
T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
Natalia Martin-Orozco et al.
IMMUNITY (2009)
Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer
Paul Salama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cutting Edge: Necrosis Activates the NLRP3 Inflammasome
Hanfen Li et al.
JOURNAL OF IMMUNOLOGY (2009)
Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy
Steve A. Broomfield et al.
JOURNAL OF IMMUNOLOGY (2009)
Vaccination With a Recombinant Protein Encoding the Tumor-specific Antigen NY-ESO-1 Elicits an A2/157-165-specific CTL Repertoire Structurally Distinct and of Reduced Tumor Reactivity Than That Elicited by Spontaneous Immune Responses to NY-ESO-1-expressing Tumors
Gilles Bioley et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors
Francois Ghiringhelli et al.
NATURE MEDICINE (2009)
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia.
Gemma G. Kenter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cyclophosphamide Chemotherapy Sensitizes Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor Growth
Robbert G. van der Most et al.
PLOS ONE (2009)
Modeling the Repertoire of True Tumor-Specific MHC I Epitopes in a Human Tumor
Nisheeth Srivastava et al.
PLOS ONE (2009)
IMMUNOLOGY Ex Uno Plura
Sonia Feau et al.
SCIENCE (2009)
Secondary Replicative Function of CD8+ T Cells That Had Developed an Effector Phenotype
Oliver Bannard et al.
SCIENCE (2009)
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Stefan Loeb et al.
NATURE REVIEWS CANCER (2009)
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
Madeleine M. Hipp et al.
BLOOD (2008)
Different immune correlates associated with tumor progression and regression: Implications for prevention and treatment of cancer
Duane H. Hamilton et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Systemic Blockade of Transforming Growth Factor-β Signaling Augments the Efficacy of Immunogene Therapy
Samuel Kim et al.
CANCER RESEARCH (2008)
The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death
T. Panaretakis et al.
CELL DEATH AND DIFFERENTIATION (2008)
Endocytosis mechanisms and the cell biology of antigen presentation
Sven Burgdorf et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Human regulatory T cells and autoimmunity
Cristina M. Costantino et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
Multiple roles for CD4(+) T cells in anti-tumor immune responses
Richard Kennedy et al.
IMMUNOLOGICAL REVIEWS (2008)
Deliberately provoking local inflammation drives tumors to become their own protective vaccine site
Connie Jackaman et al.
INTERNATIONAL IMMUNOLOGY (2008)
Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL- Tumors
Nicolas Larmonier et al.
JOURNAL OF IMMUNOLOGY (2008)
Regulatory CD4+ T cells are crucial for preventing CD8+ T cell-mediated autoimmunity
Maud Poitrasson-Riviere et al.
JOURNAL OF IMMUNOLOGY (2008)
Targeting the effector site with IFN-αβ-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors
Andrew J. Currie et al.
JOURNAL OF IMMUNOLOGY (2008)
Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation
Sven Burgdorf et al.
NATURE IMMUNOLOGY (2008)
The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
Jedd D. Wolchok et al.
ONCOLOGIST (2008)
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
Jianda Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Specificity in cancer immunotherapy
Andrea Schietinger et al.
SEMINARS IN IMMUNOLOGY (2008)
Immunological aspects of cancer chemotherapy
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Characterizing the cancer genome in lung adenocarcinoma
Barbara A. Weir et al.
NATURE (2007)
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
IMMUNOLOGICAL REVIEWS (2007)
Cognate memory CD4+ T cells generated with dendritic cell priming influence the expansion, of secondary CD8+ T cells and trafficking, and differentiation enhance tumor control
Melissa L. Hwang et al.
JOURNAL OF IMMUNOLOGY (2007)
Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference
Nathalie Chaput et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2007)
Cytotoxic T-Lymphocyte - Associated antigen-4
F. Stephen Hodi
CLINICAL CANCER RESEARCH (2007)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Structure and function: Heat shock proteins and adaptive immunity
Babak Javid et al.
JOURNAL OF IMMUNOLOGY (2007)
Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors
Matthew F. Mescher et al.
SEMINARS IN CANCER BIOLOGY (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation
Sven Burgdorf et al.
SCIENCE (2007)
Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: Implications for self-tolerance and tumor therapy
Silvie Cloosen et al.
CANCER RESEARCH (2007)
Infiltration of a mesothelioma by IFN-γ-producing cells and tumor rejection after depletion of regulatory T cells
Geordie Rudge et al.
JOURNAL OF IMMUNOLOGY (2007)
Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo
Parisa Sinai et al.
JOURNAL OF IMMUNOLOGY (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway
Brian T. Fife et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference
Xiufen Zheng et al.
JOURNAL OF IMMUNOLOGY (2006)
Combined chemoimmunotherapy of solid tumours: Improving vaccines?
Anna K. Nowak et al.
ADVANCED DRUG DELIVERY REVIEWS (2006)
Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to Vα24+ NKT cell-mediated cytotoxicity
Stephen R. Mattarollo et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
T helper lymphocytes rescue CTL from activation-induced cell death
Richard Kennedy et al.
JOURNAL OF IMMUNOLOGY (2006)
Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors
CS Bundell et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells
Ariel Savina et al.
CELL (2006)
Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells
Matthew A. Williams et al.
NATURE (2006)
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Eric A. Reits et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Immune suppression in the tumor microenvironment
TF Gajewski et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
SJ Antonia et al.
CLINICAL CANCER RESEARCH (2006)
Cranking the immunologic engine with chemotherapy: Using context to drive tumor antigen cross-presentation towards useful antitumor immunity
RG van der Most et al.
CANCER RESEARCH (2006)
Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis
NFS Watson et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma
SA Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2005)
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
V Lennerz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation
F Ghiringhelli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
E Suzuki et al.
CLINICAL CANCER RESEARCH (2005)
Opinion - Immunotherapy and chemotherapy - a practical partnership
RA Lake et al.
NATURE REVIEWS CANCER (2005)
The controversial abscopal effect
JM Kaminski et al.
CANCER TREATMENT REVIEWS (2005)
TGF-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells
M Ahmadzadeh et al.
JOURNAL OF IMMUNOLOGY (2005)
Mechanisms of suppression by suppressor T cells
H von Boehmer
NATURE IMMUNOLOGY (2005)
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
MEC Lutsiak et al.
BLOOD (2005)
Role of transforming growth factor beta in human cancer
RL Elliott et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death
EM Janssen et al.
NATURE (2005)
Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells
HY Wang et al.
JOURNAL OF IMMUNOLOGY (2005)
CD8+T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
PA Antony et al.
JOURNAL OF IMMUNOLOGY (2005)
Regulatory T cell lineage specification by the forkhead transcription factor FoxP3
JD Fontenot et al.
IMMUNITY (2005)
Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells
J Huehn et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
C Blank et al.
CANCER RESEARCH (2004)
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
F Ghiringhelli et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
CD4+CD25+ cells controlling a pathogenic CD4 response inhibit cytokine differentiation, CXCR-3 expression, and tissue invasion
N Sarween et al.
JOURNAL OF IMMUNOLOGY (2004)
Phosphatidylserine regulates the maturation of human dendritic cells
X Chen et al.
JOURNAL OF IMMUNOLOGY (2004)
Pathways of apoptotic and non-apoptotic death in tumour cells
H Okada et al.
NATURE REVIEWS CANCER (2004)
Death by design: apoptosis, necrosis and autophagy
AL Edinger et al.
CURRENT OPINION IN CELL BIOLOGY (2004)
Cutting edge: Tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation
PA Stumbles et al.
JOURNAL OF IMMUNOLOGY (2004)
Danger signals: a time and space continuum
M Skoberne et al.
TRENDS IN MOLECULAR MEDICINE (2004)
Transcriptional suppression of interleukin-12 gene expression following phagocytosis of apoptotic cells
SJ Kim et al.
IMMUNITY (2004)
IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature:: A novel mechanism for IL-21
C Jackaman et al.
JOURNAL OF IMMUNOLOGY (2003)
Molecular identification of a danger signal that alerts the immune system to dying cells
Y Shi et al.
NATURE (2003)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Phagosomes are competent organelles for antigen cross-presentation
M Houde et al.
NATURE (2003)
CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses
H Nishikawa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells
AK Nowak et al.
JOURNAL OF IMMUNOLOGY (2003)
Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells
HP Feng et al.
BLOOD (2002)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
T cell homeostatic proliferation elicits effective antitumor autoimmunity
W Dummer et al.
JOURNAL OF CLINICAL INVESTIGATION (2002)
CD8+ T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function
C Öhlén et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion
B Linard et al.
JOURNAL OF IMMUNOLOGY (2002)
The danger model: A renewed sense of self
P Matzinger
SCIENCE (2002)
Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo
M Li et al.
JOURNAL OF IMMUNOLOGY (2001)
Tumor progression despite efficient tumor antigen cross-presentation and effective arming of tumor antigen-specific CTL
DJ Nelson et al.
JOURNAL OF IMMUNOLOGY (2001)
In vivo cross-presentation of a soluble protein antigen: Kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes
D Nelson et al.
JOURNAL OF IMMUNOLOGY (2000)
Tumor-specific CD4+ T cells have a major post-licensing role in CTL mediated anti-tumor immunity
AL Marzo et al.
JOURNAL OF IMMUNOLOGY (2000)
Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity
NP Restifo
CURRENT OPINION IN IMMUNOLOGY (2000)
Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways
F Castellino et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
The critical role of Th1-dominant immunity in tumor immunology
T Nishimura et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
分享论文
